Nanofluidic digital PCR for improved selection of metastatic colorectal cancer patients to anti-EGFR therapies

被引：0
|
作者：
Azuara, D. [1 ]
Santos, C. [1 ,2 ]
Lopez-Doriga, A. [3 ]
Montal, R. [1 ,2 ]
Sanjuan, X. [4 ]
Moreno, V. [3 ]
Tabernero, J. [5 ]
Montagut, C. [6 ]
Salazar, R. [1 ,2 ]
Capella, G. [1 ]
机构：
[1] Catalan Inst Oncol IDIBELL, Translat Res Lab, Lhospitalet De Llobregat, Spain
[2] Catalan Inst Oncol IDIBELL, Dept Med Oncol, Lhospitalet De Llobregat, Spain
[3] Catalan Inst Oncol IDIBELL, Biomarkers & Susceptibil Unit, Lhospitalet De Llobregat, Spain
[4] Univ Hosp Bellvitge IDIBELL, Dept Pathol, Lhospitalet De Llobregat, Spain
[5] Vall dHebron Inst Oncol, Dept Med Oncol, Barcelona, Spain
[6] Hosp del Mar, Dept Med Oncol, Barcelona, Spain
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
699
引用
收藏
页码：S154 / S155
页数：2
相关论文
共 50 条
  • [1] Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies
    Azuara, Daniel
    Santos, Cristina
    Lopez-Doriga, Adriana
    Grasselli, Julieta
    Nadal, Marga
    Sanjuan, Xavier
    Marin, Fatima
    Vidal, Joana
    Montal, Robert
    Moreno, Victor
    Bellosillo, Beatriz
    Argiles, Guillem
    Elez, Elena
    Dienstmann, Rodrigo
    Montagut, Clara
    Tabernero, Josep
    Capella, Gabriel
    Salazar, Ramon
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (05) : 1106 - 1112
  • [2] Integrating anti-EGFR therapies in metastatic colorectal cancer
    Haraldsdottir, Sigurdis
    Bekaii-Saab, Tanios
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2013, 4 (03) : 285 - 298
  • [3] Consensus recommendations for the use of anti-EGFR therapies in metastatic colorectal cancer
    Cripps, C.
    Gill, S.
    Ahmed, S.
    Colwell, B.
    Dowden, S.
    Kennecke, H.
    Maroun, J.
    Samson, B.
    Thirlwell, M.
    Wong, R.
    CURRENT ONCOLOGY, 2010, 17 (06) : 272 - 278
  • [4] Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients
    Zlobec, Inti
    Molinari, Francesca
    Martin, Vittoria
    Mazzucchelli, Luca
    Saletti, Piercarlo
    Trezzi, Rosangela
    De Dosso, Sara
    Vlajnic, Tatjana
    Frattini, Milo
    Lugli, Alessandro
    WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (38) : 4823 - 4831
  • [5] Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients
    Inti Zlobec
    Francesca Molinari
    Vittoria Martin
    Luca Mazzucchelli
    Piercarlo Saletti
    Rosangela Trezzi
    Sara De Dosso
    Tatjana Vlajnic
    Milo Frattini
    Alessandro Lugli
    World Journal of Gastroenterology, 2010, 16 (38) : 4823 - 4831
  • [6] Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer
    Fakih, M.
    Vincent, M.
    CURRENT ONCOLOGY, 2010, 17 : S18 - S30
  • [7] KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies
    Soulieres, D.
    Greer, W.
    Magliocco, Anthony M.
    Huntsman, D.
    Young, S.
    Tsao, M-S.
    Kamel-Reid, S.
    CURRENT ONCOLOGY, 2010, 17 : S31 - S40
  • [8] Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response
    Liu, X.
    George, G. C.
    Tsimberidou, A. M.
    Naing, A.
    Wheler, J. J.
    Kopetz, S.
    Fu, S.
    Piha-Paul, S. A.
    Eng, C.
    Falchook, G. S.
    Janku, F.
    Garrett, C.
    Karp, D.
    Kurzrock, R.
    Zinner, R.
    Raghav, K.
    Subbiah, V.
    Hess, K.
    Meric-Bernstam, F.
    Hong, D. S.
    Overman, M. J.
    BMC CANCER, 2015, 15
  • [9] Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response
    X. Liu
    G. C. George
    A. M. Tsimberidou
    A. Naing
    J. J. Wheler
    S. Kopetz
    S. Fu
    S. A. Piha-Paul
    C. Eng
    G. S. Falchook
    F. Janku
    C. Garrett
    D. Karp
    R. Kurzrock
    R. Zinner
    K. Raghav
    V. Subbiah
    K. Hess
    F. Meric-Bernstam
    D. S. Hong
    M. J. Overman
    BMC Cancer, 15
  • [10] Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer
    Jose A. García-Sáenz
    Javier Sastre
    Eduardo Díaz-Rubio García
    Clinical and Translational Oncology, 2009, 11 : 737 - 747
12345